DDInter916 DDInter1376
The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a number of lifestyle changes (ie. reduced sodium intake) along with pharmacotherapy - it should be noted that treatment with several antihypertensive agents may be required in order to achieve blood pressure targets. Thiazide-like diuretics such as indapamide are a valuable tool for the treatment of hypertension and continue to grow in popularity, falling behind only ACE inhibitors in terms of prescription frequency. When compared to [hydrochlorothiazide] (another commonly prescribed diuretic), indapamide has been shown to be superior at lowering systolic blood pressure, reducing left ventricular mass index, lowering oxidative stress, inhibiting platelet aggregation, and reducing microalbuminuria associated with diabetes. Interestingly,
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Indapamide {u} (Compound) resembles {v} (Compound) Metolazone
Indapamide {u} (Compound) resembles {v} (Compound) Oxcarbazepine
Indapamide {u} (Compound) treats {v} (Disease) hypertension
Indapamide {u} (Compound) binds {v} (Gene) CA5A
Indapamide {u} (Compound) is included by {v} (Pharmacologic Class) Increased Diuresis
Indapamide {u} (Compound) causes {v} (Side Effect) Blister
Indapamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mepenzolate
Indapamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Atropine
Indapamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calcifediol
Indapamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Saxagliptin
Indapamide (Compound) resembles Metolazone (Compound)
Indapamide (Compound) resembles Oxcarbazepine (Compound)
Indapamide (Compound) treats hypertension (Disease)
Indapamide (Compound) binds CA5A (Gene)
Indapamide (Compound) is included by Increased Diuresis (Pharmacologic Class)
Indapamide (Compound) causes Blister (Side Effect)
Indapamide may cause a minor interaction that can limit clinical effects when taken with Mepenzolate
Indapamide may cause a minor interaction that can limit clinical effects when taken with Atropine
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Calcifediol
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin